Lei Zhang, a Chinese billionaire investor and hedge fund manager, founded Hillhouse Capital Management. The long-term equity strategy of Zhang’s hedge fund is focused on global investments with a particular interest in Chinese and Asian markets. Hillhouse Capital Management’s Q3 portfolio is worth $7.6 billion, with a 69.25 percent concentration in its top ten holdings. Lei Zhang primarily invests in healthcare, consumer discretionary, IT, and communications. Legend Biotech Corporation and salesforce.com, inc. were the fund’s most popular investments.
Insider Monkey highlights 10 biotech stocks to buy according to Chinese billionaire Lei Zhang. In the field of immunology and autoimmune diseases, argenx SE is working. GAAP loss per share was $3.23 and revenue was $471.26 million, an increase of 1300.5 percent from the previous year’s figure. Antiviral therapies for chronic hepatitis B and liver disease are the focus of biotechnology company Aligos Therapeutics, Inc. With 3.5 million shares worth $55 million, Vivo Capital is the largest shareholder. The Chinese billionaire Lei Zhang has added Tango Therapeutics, Inc. to his portfolio in the third quarter. In all, Zhang’s fund purchased 4.37 million shares of the company for $56.5 million, or 0.73 percent of Hillhouse Capital Management’s total investments. According to billionaire Lei Zhang, Illumina, Inc. is one of the best biotech stocks to invest in. Revenue increased by 39.55 percent from the prior year’s quarter to $1.11 billion during this time period. As we approach 2022, analysts are concerned about the prospect of difficult comparisons. CRISPR technology is being used by Beam Therapeutics Inc. to develop advanced genetic medicines. Cathie Wood’s ARK Investment Management owns 6.84 million shares worth $595.2 million as of Q3 2021, making it the largest stakeholder. For more details, click 10 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang.